THE WOODLANDS, Texas,
March 15, 2019 /PRNewswire-PRWeb/ --
Under a license agreement with the Houston Methodist Research
Institute (HMRI) for development of clinical grade RNA
manufacturing services, VGXI announced it has completed all of the
partnership's Phase I initiatives and anticipates Phase II will
conclude by 4Q 2019. The plan includes establishment and operation
of a pilot RNA production plant at the VGXI facility in parallel
with method optimization to prepare for scale-up and clinical grade
service offerings.
VGXI's experienced team is recognized among the DNA vaccine and
gene therapy industries for its flexibility in meeting challenging
client timelines and dedication to providing the highest quality
DNA products and services. The addition of RNA production and
testing in 2019 will provide an ideal complement to this service
line by leveraging deep technical knowledge and proven processes
for production of nucleic acid-based pharmaceuticals. Contact VGXI
today to learn more
ABOUT VGXI, INC.
VGXI, Inc. has over 15 years of experience and is a leading
provider of manufacturing and development services for DNA vaccines
and gene therapies. The company has a reputation of success in
manufacturing DNA products under cGMP conditions for clinical
trials in the US, EU, Asia,
Canada, and Australia, and its cGMP and non-GMP products
have passed rigorous reviews by several international regulatory
agencies. VGXI's ability to work with unique requirements and
create custom manufacturing solutions is based on its patented
manufacturing process, flexible cGMP production facility, and
experienced development team. VGXI, Inc. is a wholly-owned
subsidiary CMO of GeneOne Life Science, Inc. To learn more or
request a quote, visit http://www.vgxii.com.
ABOUT GENEONE LIFE SCIENCE
GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) is an
international DNA vaccine and product developer and leading
contract manufacturer of DNA plasmid-based agents for pre-clinical
and clinical trials for global companies and institutions. It
researches and develops DNA vaccines and products to prevent and
treat incurable diseases in South
Korea and internationally. The company is headquartered in
Seoul, South Korea. VGXI, Inc.,
GeneOne's wholly-owned manufacturing subsidiary located in
Texas, is the largest pure-play
cGMP DNA plasmid manufacturing facility in the world. For more
information, visit http://www.genels.com/en.
ABOUT HOUSTON METHODIST
Houston Methodist Hospital is ranked as one of the nation's best
hospitals and the #1 hospital in Texas by US News & World Report. The
Houston Methodist central campus includes the flagship hospital and
the Houston Methodist Research Institute, located in the heart of
the Texas Medical Center, the largest medical center in the world.
The RNAcore at the Research Institute, directed by professor and
chair, John Cooke, MD, PhD is a
leader in RNA synthesis and generate both research and clinical
grade RNA constructs including mRNA, modified mRNA (mmRNA),
microRNA cassettes, and noncoding RNA. In addition to manufacturing
methods, the RNAcore has also developed exceptional technologies
for improved stability of RNA products and enhanced delivery of
nucleic acid based therapies. Beginning as a core group for the
Progenitor Cell Biology Consortium of the National Heart, Lung, and
Blood Institute, the RNAcore is now also supported by the Cancer
Prevention Research Institute of Texas, to further the development of
cutting-edge RNA technologies. For more information, visit
http://houstonmethodist.org/RNAcore.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
Materials in this press release contain information that includes
or is based upon forward-looking statements within the meaning of
the Securities Litigation Reform Act of 1995. Forward-looking
statements relate to expectations or forecasts of future events.
These statements can be identified by the fact that they do not
relate strictly to historical or current facts. They include words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with a discussion of potential future events,
circumstances or future operating or financial performance. In
particular, these include statements relating to future actions,
prospective products or product approvals, future performance or
results of current and anticipated products, sales efforts,
expenses, the outcome of contingencies such as legal proceedings,
and financial results. Any or all of our forward-looking statements
here or in other publications may turn out to be incorrect. They
can be affected by inaccurate assumptions or by known or unknown
risks and uncertainties. Many such factors will be important in
determining our actual future results. Consequently, no
forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product
availability, current and future branded and generic competition,
federal and state regulations and legislation, manufacturing
issues, timing of the elimination of trade buying, patent
positions, litigations and investigations. Our actual results may
vary materially, and there are no guarantees about the performance
or valuation of GeneOne stock. It is also important to read the
disclosure notice contained in many of the individual GeneOne
documents available on the website, as many contain important
information on such cautionary factors as of the date of the
individual document. We undertake no obligation to correct or
update any forward-looking statements, whether as a result of new
information, future events or otherwise. You are advised, however,
to consult any further disclosures we make on related subjects in
our reports.
SOURCE VGXI